 Inflammatory bowel disease, IBD, is a chronic gastrointestinal disorder characterized by inflammation of the digestive tract. It is caused by a combination of genetic and environmental factors and can lead to serious complications such as malnutrition, bleeding, and even cancer. Guv microbiota dysbiosis, or imbalance of the bacteria in the gut, is believed to play a key role in the development of IBD. Studies have found that certain types of bacteria may contribute to the progression of IBD, while others may help reduce symptoms. Researchers are exploring the use of probiotics and prebiotics as treatments for IBD, as they may help restore balance to the gut microbiome and reduce inflammation. This article was authored by Izoracan, Naimola, Legeasha, and others.